Mithra Pharmaceuticals S.A.

AGM Information • May 20, 2021

Mithra's General Meeting of Shareholders Approves the Renewal of its Board of Directors

Liege, Belgium, 20 May 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today held its Annual General Meeting of securities holders. All agenda items put to vote were approved, including the appointment of Directors for a two-year-mandate.

The new Board of directors will count 10 directors with varied and complementary profiles, allowing Mithra to have proven expertise in all the fields covering pharmaceutical products development. For the first time, this board will have a perfect parity with 5 women directors and 5 men directors, as well as 5 independent and 5 non-independent directors.

Parity and multidisciplinary expertise

Mr. Ajit Shetty will become Chairman of the Board in June, succeeding Ms. Patricia van Dijck (Market Access & Public Affairs Director at GSK) who will remain on the Board as Independent Director. Mr Shetty has served as Chairman of the Board of Janssen Pharmaceutica until 2012 and has led the global supply chain at Johnson & Johnson, the world's number 1 healthcare company. Elected Flanders Manager of the Year in 2004, Ajit Shetty is also a director of VOKA and a member of GS1.

The Board namely will include 4 new Directors appointed today:

• Ms. Liesbeth Weynants (Independent Director) holds a Master's degree in Law from the University of Leuven and is specialized in pharmaceutical and regulatory law with a focus on the life sciences sector. Ms. Weynants has extensive expertise in intellectual property and patent law for innovative medicines (AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, J&J, Lundbeck, Merck, Novartis, Sanofi,...). She is currently Managing Partner at the law firm Hoyng Rokh Monegier and Professor of Intellectual Property Law at the VUB (see resume).
• Ms. An Cloet (Independent Director) holds a Master's degree in Pharmacy from the University of Leuven and a Degree in Business and Administration from the University of Louvain. Ms. Cloet has over 25 years of pharmaceutical experience in multiple therapeutic domains, in particular women's health (contraception, osteoporosis, fertility). She built her career within MSD, where she has held various positions in Business Development, Marketing and Corporate Strategy. Ms Cloet is currently External Affairs Director (see resume).
• Ms Amel Tounsi (Non-executive Director) holds a PhD in Biomedical and Pharmaceutical Sciences from the University of Louvain and has a broad experience in cell-therapy development. During her career in the biotech sector (Celyad, Texere, Analis, Masthercell), she acquired a strong expertise in Business Development and Company Development strategy. She is currently Investment Manager at Noshaq (see resume).
• Ms. Valérie Gordenne (Non-executive Director) holds a Master's degree in Pharmacy from the University of Liège and has more than 20 years of experience in pharmaceutical Research & Development, and more specifically in full drug development across a range of therapeutic areas, in particular in women's health (CSO Mithra, CEO Novalon, General Manager Odyssea

Pharma). She is currently Chief Scientific Officer at Auxin Surgery, CEO of the start-up Odix and advisor in regulatory affairs.(see resume).

The General Meeting also approved the appointment of Mr. Erik Van Den Eynden (CEO of Straco) as Independent Director following his cooptation last November, and renewed the mandates of Mr. Gaëtan Servais (CEO of Noshaq) as Non-executive Director, of Mr. François Fornieri (co-founder of Mithra) as Non-executive Director and of Mr. Jean-Michel Foidart (co-founder of Mithra and Permanent Secretary of the Belgian Royal Academy) as Executive Director.

Mr. Stijn Van Rompay, who was expected to join the Board of Directors in November 2020¹ , has finally decided to withdraw his application, following the appointment of his father Leon Van Rompay as CEO in February 2021. In the context of the health crisis, Jean Stéphenne is currently not available to assume a new board position in addition to his current priority mission within the biotech company CureVac.

"I am extremely honored to serve as Mithra's next president in this historic year that marks its transition to a global commercial company ", commented Ajit Shetty. "I would like to thank Mrs. Patricia van Dijck for her dedication and professionalism during her chairmanship, as well as Mr. Christian Moretti and Mr. Koen Hoffman who have been key directors to the company's development. We now have a strong and balanced Board, with directors who are experts in a variety of fields that are essential for the future of the company. We are determined to deploy the multiple potentialities of Mithra and to support it in the development of its numerous promising projects ".

********

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women health and beyond (Covid-19, neuroprotection…). Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and

¹ Press release Mithra, 3/11/2021

uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media : Linkedin • Twitter • Facebook

investors.mithra.com • 3